| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA678: Omalizumab for treating chronic rhinosinusitis with nasal polyps (terminated) |
|
Medicine details |
|
| Medicine name | omalizumab (Xolair®) |
| Formulation | 75 mg and 150 mg subcutaneous injection |
| Reference number | 3681 |
| Indication | As an add-on therapy with intranasal corticosteroids (INC) for the treatment of adults (18 years and above) with severe CRSwNP [Chronic rhinosinusitis with nasal polyps] for whom therapy with INC does not provide adequate disease control |
| Company | Novartis Pharmaceuticals UK Ltd |
| BNF chapter | Ear, nose & oropharynx |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 13/05/2021 |
| NICE guidance | TA678: Omalizumab for treating chronic rhinosinusitis with nasal polyps (terminated) |